Heart Failure
Conditions
Brief summary
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting. The trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient. The hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation. Primary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation. Secondary objective(s) are to evaluate patient outcomes and graft function post-transplant. HOPE for All is a prospective, single-armed single-centre proof-of-consept trial.
Detailed description
HOPE for All will include a total of 20 subjects transplanted with donor hearts using the revised XVIVO Heart Assist Transport System and will evaluate transplant outcomes such as patient survival, post-transplant complications and graft function for a period of 12 months post-transplant. The investigation will be conducted at 1 heart transplant center in Belgium who has thorough experience using the XVIVO Heart Assist Transport System for both DBD and DCD transplants. The study will not include a control group as this is a proof-of-concept study
Interventions
Revised XHAT
Sponsors
XVIVO Perfusion
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Recipient: 1. Age ≥18 years 2. Signed informed consent form 3. Accepted or listed for heart transplantation Inclusion Criteria Heart Donor: 1. Accepted as a heart donor by the transplant team based on current standard of care criteria 2. DBD or DCD Maastricht category III or euthanasia donors
Exclusion criteria
Recipient: 1. Not able to understand the information provided during the informed consent procedure 2. Combined organ transplantation candidates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient Survival | 30 days post-transplant |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac related mortality at 30 days post-transplant | 30 days post-transplant |
| Incidence of Mechanical circulatory support within 30 days post-transplant | 30-days post-transplant |
| Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant | 24 hours post-transplant |
| Incidence of Primary Graft Dysfunction (PGD) RV at 24 hours post-transplant | 24 hours post-transplant |
| Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant | 24 hours and 30 days post-transplant |
| Duration of initial ICU stay after the index procedure | 30-days post-transplant |
| Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime) within 30 days post-transplant | 30 days post-transplant |
| Incidence of hearts perfused on the investigational device which is not used for transplantation | From enrollment to the end of recruitment |
| Cardiac related mortality at 6 and 12 months post-transplant | 6 and 12 months post-transplant |
| Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 6 and 12 months post-transplant | 6 and 12 months post-transplant |
| Number of days until hospital discharge from index procedure 6 and 12 months post-transplant | 6 and 12 months post-transplant |
| Incidence of biopsy proven rejections > 1 ACR leading to changed immunosuppressive regime within 12 months post-transplant | Within 12 months post-transplant |
Countries
Belgium
Contacts
CONTACTFilip Rega, MD, PhD
CONTACTJanne Brouckaert, MD
Outcome results
None listed